- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Community-acquired Pneumonia AND Lobar Pneumonia.
Displaying page 1 of 1.
| EudraCT Number: 2007-001735-66 | Sponsor Protocol Number: NXL103/2001 | Start Date*: 2007-10-01 | |||||||||||
| Sponsor Name:Novexel S. A. | |||||||||||||
| Full Title: A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL... | |||||||||||||
| Medical condition: Community-Acquired Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003971-20 | Sponsor Protocol Number: CE01-300 | Start Date*: 2013-05-07 | |||||||||||
| Sponsor Name:Cempra Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Ac... | |||||||||||||
| Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) ES (Completed) PL (Completed) LV (Completed) EE (Completed) BG (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003026-14 | Sponsor Protocol Number: ML-3341-306 | Start Date*: 2016-02-04 | |||||||||||
| Sponsor Name:Melinta Therapeutics, Inc. | |||||||||||||
| Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTE... | |||||||||||||
| Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) ES (Completed) LV (Completed) BG (Completed) DE (Completed) SI (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003453-13 | Sponsor Protocol Number: CE01-301 | Start Date*: 2014-06-18 | |||||||||||
| Sponsor Name:Cempra Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad... | |||||||||||||
| Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002203-18 | Sponsor Protocol Number: P903-31 | Start Date*: 2012-07-18 | ||||||||||||||||||||||||||
| Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | ||||||||||||||||||||||||||||
| Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With... | ||||||||||||||||||||||||||||
| Medical condition: Community-acquired Bacterial Pneumonia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-002683-32 | Sponsor Protocol Number: DUR001-305 | Start Date*: 2015-03-30 | |||||||||||
| Sponsor Name:Durata Therapeutics International B.V. | |||||||||||||
| Full Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia | |||||||||||||
| Medical condition: Community acquired bacterial pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004039-37 | Sponsor Protocol Number: CE01-203 | Start Date*: 2014-10-10 |
| Sponsor Name:Cempra Pharmaceuticals, Inc. | ||
| Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ... | ||
| Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP) | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002798-21 | Sponsor Protocol Number: WI18273 | Start Date*: 2005-02-18 |
| Sponsor Name:F.Hoffmann-La Roche Ltd | ||
| Full Title: A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitaliza... | ||
| Medical condition: Community-acquired pneumonia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: LV (Completed) HU (Completed) SK (Completed) LT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
| Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
| Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000736-37 | Sponsor Protocol Number: 1001 | Start Date*: 2022-08-12 | ||||||||||||||||
| Sponsor Name:Biotest AG | ||||||||||||||||||
| Full Title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneu... | ||||||||||||||||||
| Medical condition: non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Prematurely Ended) HU (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) LT (Trial now transitioned) PT (Trial now transitioned) SK (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-021574-11 | Sponsor Protocol Number: 32729463CAP2001 | Start Date*: 2011-01-24 | |||||||||||
| Sponsor Name:Furiex Pharmaceuticals, Inc | |||||||||||||
| Full Title: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospita... | |||||||||||||
| Medical condition: Community-Acquired Bacterial Pneumonia (CABP) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004782-92 | Sponsor Protocol Number: NAB-BC-3781-3102 | Start Date*: 2016-07-26 | |||||||||||
| Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia | |||||||||||||
| Medical condition: Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and consid... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) HU (Completed) ES (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-005169-63 | Sponsor Protocol Number: NAB-BC-3781-3101 | Start Date*: 2016-01-12 | |||||||||||
| Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community... | |||||||||||||
| Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-005097-25 | Sponsor Protocol Number: KIDS-STEP | Start Date*: Information not available in EudraCT |
| Sponsor Name:Universitätskinderspital beider Basel (UKBB) | ||
| Full Title: A randomised placebo-controlled multi-centre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community acquired pneumonia (CAP) | ||
| Medical condition: Children with community acquired pneumonia (CAP). | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000809-36 | Sponsor Protocol Number: CAP-IT | Start Date*: 2016-09-30 |
| Sponsor Name:Medical Research Council Clinical Trials Unit at UCL | ||
| Full Title: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial. | ||
| Medical condition: Pneumonia | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Completed) IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002479-28 | Sponsor Protocol Number: MOL-ARDS-002 | Start Date*: 2015-09-24 | |||||||||||
| Sponsor Name:Justus-Liebig University | |||||||||||||
| Full Title: GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration | |||||||||||||
| Medical condition: Pneumonia associated Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.